Peptide Stack

SS-31 + MOTS-c

Elamipretide MOTS-c · mitochondrial stack · SS-31/MOTS-c

Named mitochondrial blend of SS-31 (elamipretide) plus MOTS-c. Elamipretide is FDA accelerated-approved as Forzinity™ for Barth syndrome ≥30 kg (Sep 2025) - that product is not this stack. MOTS-c remains research-only. Gray-market combo vials are not a Barth protocol and are not an approved combination.

Not FDA-approved - research chemical

Quick answer

What it is: Named mitochondrial blend of SS-31 (elamipretide) plus MOTS-c.

Typical research dose: Research vials vary; not the Forzinity Barth dose. MOTS-c often 5-10 mg/week in community protocols

Reconstitution calculator ↓NAD+ injections online: providers and cost →Telehealth clinics that prescribe peptides →

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team

·Last updated: August 2026·Evidence: Low·1 peer-reviewed citation

Typical research dose

Research vials vary; not the Forzinity Barth dose. MOTS-c often 5-10 mg/week in community protocols

Frequency

SS-31 often daily in trials · MOTS-c several times weekly

Half-life

~4 h (elamipretide) / estimated hours (MOTS-c)

Common vials

10 mg

CAS

N/A (blend)

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Longevity / aging2/10
Two research SKUs in one bottle. Not a combination trial. Not Forzinity.

Compound card

Class: Vendor mitochondrial blend (elamipretide + MOTS-c)
Formula: Elamipretide + MOTS-c
Status: Not FDA-approved · research use

Dose it

10 mg + 2 mL BAC water → 5 mg/mL · advertised cake. Confirm the COA, then use the blend calculator.

Open blend calculator

How it works

SS-31 (elamipretide) binds cardiolipin on the inner mitochondrial membrane. MOTS-c is a 16-aa peptide encoded in the mitochondrial 12S rRNA region, studied as an AMPK-linked metabolic signal.

Elamipretide received FDA accelerated approval in September 2025 as Forzinity™ for Barth syndrome in patients ≥30 kg. That is a single-agent, single-indication product. This stack is a research-chem pairing. Do not copy Forzinity dosing onto a blended vial.

Source: MOTS-c PMID: 25738459; Forzinity FDA accelerated approval Sep 2025

Not Forzinity

Forzinity is elamipretide for Barth syndrome. MOTS-c is not on that label. A gray-market combo is not mitochondrial-disease care.

Research Use Cases

✓Barth syndrome: High
✓Research stack SKU: Low

Dosing

Phase	Dose	Frequency	Notes
Approved elamipretide	Forzinity PI only	Per label	Barth syndrome ≥30 kg. Not this stack.
Research blend	Vendor-defined	Vendor-defined	Calculator is vial math. Not a protocol.

Administration

Route / form

Subcutaneous (research vials)

Timing

Not established for the combo.

Empty stomach?

No - Food timing is not critical.

Timeline

Label (Forzinity)

Barth muscle-strength intermediate endpoint - not a biohacking timeline.

Who it is for

Barth syndrome

High

That is Forzinity (elamipretide alone), prescribed. Not this page.

Research stack SKU

Low

Two mitochondrial-adjacent peptides in one bottle. No combo approval.

Reconstitution

Vial	Water	Concentration	Example dose
10 mg lyophilized	2 mL BAC	5 mg/mL	Blend SKU. Confirm each peptide mg on the COA before using catalog 10 mg / 2 mL math.

Change vial size or water volume? Open the blend calculator.

Safety & Considerations

Elamipretide is a prescription drug for a rare disease. MOTS-c has no human approval. Mixing them does not create a sports-performance protocol. Injection-site reactions; unknown combo safety.

Regulatory & Legal Status

FDA Status (US)

Research Only

SS-31 is Forzinity™ for Barth syndrome alone. MOTS-c is research-only. The blend is not approved

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

No combined RCT.
Barth-syndrome labeling does not travel to a combo cake.

Verdict

A named blend of SS-31 and MOTS-c. Forzinity is not this stack. MOTS-c remains research-only. Use the singles for identity; use the blend calculator for math.

Interactions & Contraindications

Elamipretide is a prescription drug for a rare disease. MOTS-c has no human approval. Mixing them does not create a sports-performance protocol. Injection-site reactions; unknown combo safety.

SS-31 + MOTS-c vs. SS-31 (elamipretide)

Canonical comparison: SS-31 + MOTS-c vs SS-31 (elamipretide)

Attribute	SS-31 + MOTS-c	SS-31 (elamipretide)
Identity	Elamipretide + MOTS-c blend	Elamipretide alone
FDA	Not an approved combination	Forzinity™ accelerated approval (Barth, Sep 2025)
Job	Vendor mitochondrial stack	Labeled Barth product or research vial

Verdict: The stack is not Forzinity. Elamipretide’s approval is a single-agent, single-indication story.

Frequently Asked Questions

Is SS-31 FDA-approved?▼

Elamipretide is Forzinity, accelerated approval Sep 2025 for Barth syndrome ≥30 kg. Research vials and this blend are not that product.

Can I use Forzinity doses in this calculator?▼

No. Use the PI. This leaf is identity for a vendor stack plus reconstitution arithmetic.

References

Lee C et al. “MOTS-c is a mitochondrial-encoded peptide.” Cell Metabolism (2015). PMID: 25738459

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →

← Back to Peptide Library